Femcon Fe

Femcon Fe is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):

FEMCON FE (ethinyl estradiol; norethindrone - tablet, chewable; oral)

• 
  Manufacturer: WARNER CHILCOTT
  
  Approval date: November 14, 2003
  
  Strength(s): 0.035MG;0.4MG ^[RLD][AB]

Has a generic version of Femcon Fe been approved?

A generic version of Femcon Fe has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Femcon Fe and have been approved by the FDA:

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ethinyl estradiol; norethindrone tablet, chewable; oral)

• 
  Manufacturer: BARR
  
  Approval date: August 5, 2010
  
  Strength(s): 0.035MG;0.4MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: September 26, 2011
  
  Strength(s): 0.035MG;0.4MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Femcon Fe. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Chewable oral contraceptive
  Patent 6,667,050
  Issued: December 23, 2003
  Inventor(s): Roger M.; Boissonneault & Tina M.; deVries
  Assignee(s): Galen (Chemicals) Limited
  The present invention relates to a chewable, palatable oral contraceptive tablet, comprising an oral contraceptive agent, a chewable carrier suitable for human consumption, and not comprising a ferrocene compound, as well as use of these tablets in a method of human female oral contraception, and in a method of enhancing compliance with a human female oral contraceptive regimen.
  
  Patent expiration dates:
  
  
  • April 6, 2019
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
    ✓ 
    Drug product
  
  

See also...

• Femcon Fe Chewable Tablets Consumer Information (Wolters Kluwer)
• Femcon FE Consumer Information (Cerner Multum)
• Ortho-Novum Consumer Information (Drugs.com)
• Norethindrone/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Norethindrone/Ethinyl Estradiol (HRT) Consumer Information (Wolters Kluwer)
• Norethindrone/Ethinyl Estradiol Chewable Tablets Consumer Information (Wolters Kluwer)
• Norethindrone/Ethinyl Estradiol Tablets Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and norethindrone Consumer Information (Cerner Multum)
• Ethinyl estradiol and norethindrone HRT Consumer Information (Cerner Multum)
• Norethindrone, ethinyl estradiol, and ferrous fumarate Advanced Consumer Information (Micromedex)